Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMT1 | P30419 | 1/20 | 0.54 |
| ▸ | RAD52 | P43351 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | SLC16A3 | O15427 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | FABP4 | P15090 | 1/20 | 0.43 |
| ▸ | WDR5 | P61964 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3553635 | 0.88 | PKM (0.51) | RAD52L3MBTL1LMNAMAPTSLC16A3 | |
| SCHEMBL3551102 | 0.87 | RAD52 (0.50) | RAD52L3MBTL1LMNAMAPTTDP1 | |
| SCHEMBL3555623 | 0.87 | WDR5 (0.52) | NMT1F2FABP4WDR5POLB | |
| SCHEMBL3559421 | 0.83 | ALDH1A1 (0.49) | NMT1F2WDR5KMT2APOLB | |
| SCHEMBL3561108 | 0.81 | NPSR1 (0.55) | RAD52L3MBTL1LMNAMAPTSLC16A3 | |
| SCHEMBL3558660 | 0.81 | MEN1 (0.65) | RAD52L3MBTL1LMNAMAPTTDP1 | |
| SCHEMBL3562888 | 0.81 | SLC16A3 (0.64) | L3MBTL1LMNAMAPTSLC16A3TDP1 | |
| SCHEMBL3563355 | 0.80 | SLC16A3 (0.61) | NMT1RAD52SLC16A3TDP1F2 | |
| SCHEMBL3560597 | 0.79 | NMT1 (0.45) | NMT1L3MBTL1LMNAMAPTF2 | |
| SCHEMBL3560287 | 0.79 | SLC16A3 (0.64) | RAD52LMNAMAPTSLC16A3PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | claimed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | claimed |
| US-7816397-B2 | Phenylcarboxylic acid derivatives and use thereof for the treatment of diabetes | MERCK PATENT GMBH (DE) | 2010-10-19 | — | — | US | disclosed |
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | MERCK PATENT GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045483-A1 | Phenylcarboxylic Acid Derivatives and Use Thereof for the Treatment of Diabetes | SLC5A1, ALDH7A1, ASS1 | NMT1 1573/4885RAD52 4737/4885L3MBTL1 2080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.